



PTO/SB/D8A (10-96)  
Approved for use through 10/31/99. GMS 065-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

RECEIVED  
SEP 24 2007  
TECHNICAL CENTER  
PTO/STDBA (10-96)  
3199, OM 0655-0031  
DEPT. OF COMMERCE  
1600/2900


**Complete if Known**

Application Number	09/807,558
Filing Date	July 17, 2001
First Named Inventor	Stefan Dietmat Anker
Group Art Unit	1647
Examiner Name	
Attorney Docket Number	ICI 102

(use as many sheets as necessary)

1 of 8

[illegible][illegible]

Examine Signature		Date Considered	4/24/04	04/24/04
----------------------	---	-----------------	---------	----------

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

Please type a plus sign (+) inside this box →



Approved for use through 10/2/00 OMB 0651-003  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)



Sheet 2 of 8

Application Number	09/807,558
Filing Date	July 17, 2001
First Named Inventor	Stefan Dietmar Anker
Group Art Unit	1647
Examiner Name	
Attorney Docket Number	ICI 102

## OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
FH		ANKER & COATS, "Cardiac Cachexia. A syndrome with impaired survival and immune and neuroendocrine activation," <i>Chest</i> 115:836-847 (1999).	
		ANKER & RAUCHHAUS, "Insights into the pathogenesis of chronic heart failure: immune activation and cachexia," <i>Curr Opin Cardiol</i> 14(3):211-216 (1999).	
		ANKER, "Catecholamine levels and treatment in chronic heart failure," <i>Eur. Heart J.</i> 19(Suppl F.):56-61 (1998).	
		ANKER, "Relation between serum uric acid and lower limb blood flow in patients with chronic heart failure," <i>Heart</i> 78:39-43 (1997).	
		ANKER, et al., "Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure," <i>European Heart Journal</i> 20:683-693 (1999).	
		ANKER, et al., "Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia," <i>Circulation</i> 96:526-534 (1998).	
		ANKER, et al., "Loss of bone mineral in patients with cachexia due to chronic heart failure," <i>Am J Cardiol</i> 83:612-615 (1999).	
		ANKER, et al., "The influence of muscle mass, strength, fatigability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure," <i>European Heart Journal</i> 18:259-269 (1997).	
		ANKER, et al., "Tumor necrosis factor and steroid metabolism in chronic heart failure: Possible relation to muscle wasting," <i>J Amer Coll Cardiol</i> 30:997-1001 (1997).	
		ANKER, et al., "Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure," <i>Q. J. Med.</i> 91:199-203 (1998).	

Examiner's Signature	<i>Forne Hamad</i>	Date Considered	4/24/04
----------------------	--------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



Approved for use through 10/31/99. PTO/SB/08A (10-96)  
 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)



Application Number	09/807,558
Filing Date	July 17, 2001
First Named Inventor	Stefan Dietmat Anker
Group Art Unit	1644 1647
Examiner Name	
Attorney Docket Number	ICI 102

RECEIVED  
 SEP 24 2001  
 TECH CENTER 1600/2900

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
FH		BENEDICT & GRAHAME-SMITH, "Plasma adrenaline and noradrenaline concentrations and dopamine-b-hydroxylase activity in myocardial infarction with and without cardiogenic shock," <i>British Heart Journal</i> 42:214-220 (1979).	
		BERNE, "Effect of epinephrine and norepinephrine on coronary circulation," <i>Circ Res</i> 6:644-655 (1958).	
		BESARB, et al., "The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epotein," <i>N Eng J Med</i> 339(9):584-590 (1998).	
		BRINK, et al., "Angiotension II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism," <i>J Clin Invest</i> 97(11):2509-2516 (1996).	
		CHILAIN, et al., "Adrenergic coronary tone during submaximal exercise in the dog is produced by circulating catecholamines," <i>Cir Res</i> 58:68-82 (1986).	
		CHUA, et al., "Relation between chemosensitivity and the ventilatory response to exercise in chronic heart failure," <i>J Am Coll Cardiol</i> 27:650-657 (1996).	
		COATS, "Symptoms and quality of life in heart failure: the muscle hypothesis," "Symptoms and quality of life in heart failure: the muscle hypothesis," <i>Br. Heart J</i> 72:S36-S39 (1994).	
		COWIE, et al., "The epidemiology of heart failure," <i>European Heart Journal</i> 18:208-225 (1997).	
		DANERYD, et al., "Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: A randomized prospective study," <i>Cancer Res.</i> 58(23):5374-5379 (1998).	
		DAVENPORT, "Characterization of [ <sup>125</sup> I]-PD164333, an ET <sub>A</sub> selective non-peptide radiolabelled antagonists, in normal and diseased human tissues," <i>Br. J Pharmacol</i> 123(2):223-30 (1998).	

Examiner's Signature	<i>For Hand</i>	Date Considered	4/24/04
----------------------	-----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



Approved for use through 10/31/99 PTO Form 1008A (10-96)  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	09/807,558
Filing Date	July 17, 2001
First Named Inventor	Stefan Dietmar Anker
Group Art Unit	1647
Examiner Name	
Attorney Docket Number	ICI 102

Sheet 4 of 8



RECEIVED  
SEP 24 2001  
PTO CENTER 1600/2900

## OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T‡
FH		DOHERTY, et al., "In vitro and in vivo studies with a series of hexapeptide endothelin antagonists," <i>J Cardiovascular Pharmacology</i> 22(Suppl 8):S98-S102 (1993).	
		D'USCIO, et al., "Effects of chronic ET <sub>A</sub> -receptor blockade in angiotensin II-induced hypertension," <i>Hypertension</i> 29(1 Pt. 2):435-41 (1997).	
		FRANCIS, "Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure," <i>Circulation</i> 82:1724-1729 (1990).	
		GAGNON & BRUERA, "A review of the drug treatment of cachexia associated with cancer," <i>Drugs</i> 55(5):675-688 (1998).	
		GOLDSTEIN, "Plasma norepinephrine as an indicator of sympathetic neural activity in clinical cardiology," <i>Am J Cardiol</i> 48:1147-54 (1981).	
		GORTER, "Management of anorexia-cachexia associated with cancer and HIV infection," <i>Oncology</i> 5(9):13-17 (1991).	
		GREENBAUM, et al., "Host cathepsin D response to tumor in the normal and pepstatin-treated mouse," <i>Cancer Res.</i> 43(6):2584-2587 (1983).	
		HARRIS, "Congestive cardiac failure: central role of the arterial blood pressure," <i>Br Heart J</i> 58:190-203 (1987).	
		HASHIDA, "Inhibitions by E-64 derivatives of rat liver cathepsin B and cathepsin L <i>in vitro</i> and <i>in vivo</i> ," <i>J Biochem</i> 88:1805-1811 (1980).	
		HEUSCH & DEUSSEN, "The effects of cardiac sympathetic nerve stimulation on perfusion of stenotic coronary arteries in the dog," <i>Circ Res</i> 53:8-15 (1983).	

Examiner's Signature	<i>For Hand</i>	Date Considered	4/24/04
----------------------	-----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Unique citation designation number. ‡ See attached Kinds of U.S. Patent Documents. § Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¶ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*\* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. \*\*\* Applicant to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



Approved for use through 10/31/99. PTO FORM 08A (10-96)  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		Application Number	09/807,558	
		Filing Date	July 17, 2001	
		First Named Inventor	Stefan Dietmat Anker	
		Group Art Unit	1644 1647	
		Examiner Name		
5	of	8	Attorney Docket Number	ICI 102



RECEIVED  
 SEP 24 2001  
 PTO CENTER 600/2900

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
PH		HEUSCH, "α-Adrenergic mechanisms in myocardial ischemia," <i>Circulation</i> 81:1-13 (1990).	
		HUANG, et al., "Aldosterone therapy in severe chronic congestive heart failure," <i>Zhonghua Xinxueguanbing Zazhi</i> 24(1):12-15 (1996).	
		IHARA, et al., "In vitro biological profile of a highly potent novel endothelial (ET) antagonist BQ-123 selective for the ET <sub>A</sub> receptor," <i>J Cardiovasc Pharmacol</i> 20(Suppl. 12):S11-S14 (1992).	
		ISHIKAWA, et al., "Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788," <i>Proc Natl Acad Sci USA</i> 91:4892-4892 (1994).	
		JAE, et al., "Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ET <sub>A</sub> /ET <sub>B</sub> mixed antagonists," <i>J Med Chem</i> 40:3217-3227 (1997).	
		KALIMI, et al., "Effects of antimineralocorticoid RU 26752 on steroid-induced hypertension in rats," <i>Am J Physiol</i> 258(5, Pt 1):E737-9 (1990).	
		KICHUK, et al., "Angiotension-converting enzyme inhibitors promote nitric oxide production in coronary microvessels from failing explanted human hearts," <i>Am J Cardiol</i> 80:137A-142A (1997).	
		KIM, et al., "Evaluation of RU28318 and RU40555 as selective mineralocorticoid receptor and glucocorticoid receptor antagonists, respectively: receptor measures and functional studies," <i>J Steroid Biochem Mol Biol</i> 67(3):213-22 (1998).	
		LEY, et al., "Sex- and menopause-associated changes in body-fat distribution," <i>Am J Clin Nutr</i> 55:950-4 (1992).	
		LEZA, et al., <i>Revista de Farmacologia Clinica y Experimental</i> 4/4:377-383 (1987).	

Examiner's Signature	<i>[Signature]</i>	Date Considered	4/24/04
----------------------	--------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



Approved for use through 10/31/99. OMB 0651-0035  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 8

Application Number	09/807,558
Filing Date	July 17, 2001
First Named Inventor	Stefan Dietmar Anker
Group Art Unit	1644 1647
Examiner Name	
Attorney Docket Number	ICI 102



RECEIVED  
SEP 24 2001  
TEC CENTER 1600/2900

## OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
FH		LIU, et al., "Pyrrolidine-3-carboxylic acids as endothelin antagonists. 3. Discovery of a potent, 2-nonyl, highly selective ET <sub>A</sub> antagonist (A-261546)," <i>J Med Chem</i> 41:3261-3275 (1998).	
		MAGUIRE, et al., "Affinity and selectivity of PD156707, a novel nonpeptide endothelin antagonist, for human ET <sub>A</sub> and ET <sub>B</sub> receptors," <i>J Pharmacol Exp Ther</i> 280(2):1102-8 (1997).	
		MCDONALD, et al., "Plasma-catecholamines after cardiac infarction," <i>Lancet</i> 2:1021-1023 (1969).	
		MIHARA, et al., "Binding characterization of [ <sup>3</sup> H]S-0139, an antagonist of the endothelin ET <sub>A</sub> receptor subtype," <i>Eur J Pharmacol</i> 342:2-3:319-24 (1998).	
		MIYATA, et al., "WS-7338, New endothelin receptor antagonists isolated from <i>Streptomyces</i> sp. No. 7338. II. Biological characterization and pharmacological characterization of WS-7338 B," <i>J Antibiot (Tokyo)</i> 45(1):83-7 (1992).	
		MUELLER & AYRES, "Propranolol decreases sympathetic nervous activity reflected by plasma catecholamines during evolution of myocardial infarction in man," <i>J Clin Invest</i> 65:338-346 (1980).	
		MUELLER, et al., "Cardiac catecholamine response during evolving myocardial infarct in man," <i>Circulation</i> 62(Suppl III):III-81 (1980).	
		NAMBI, et al., "Nonpeptide endothelin receptor antagonists. 1. Effects on binding and signal transduction on human endothelin <sub>A</sub> and endothelin <sub>B</sub> receptors," <i>J Pharmacol Exp Ther</i> 271(2):755-61 (1994).	
		NYCANDER, et al., "Two-step mechanism of inhibition of cathepsin B by cystatin C due to displacement of the proteinase occluding loop," <i>FEBS Lett</i> 422:61-64 (1998).	
		OHSHITA, et al., "Effects of selective inhibition of cathepsin B and general inhibition of cysteine proteinases on lysosomal proteolysis in rat liver in vivo and in vitro," <i>N Eur J Biochem</i> 209(1):223-31 (1992).	

Examiner's Signature	<i>[Signature]</i>	Date Considered	4/24/04
----------------------	--------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →




Approved for use through 10/3/99 OMB 0651-0033  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known



# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 8

Application Number	09/807,558
Filing Date	July 17, 2001
First Named Inventor	Stefan Dietmar Anker
Group Art Unit	164 1647
Examiner Name	
Attorney Docket Number	ICI 102

## OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
FH		PACKER, "The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure," <i>J Am Coll Cardiol</i> 20:248-254 (1992).	
		PIEPOLI, et al., "Contribution of muscle afferents to the hemodynamic, autonomic and ventilatory responses to exercise in patients with chronic heart failure," <i>Circulation</i> 93(5):940-952 (1996).	
		POMIKOWSKI, et al., "Augmented peripheral chemosensitivity as a potential input to baroreflex impairment and autonomic imbalance in chronic heart failure," <i>Circulation</i> 96(8):2586-2594 (1997).	
		RAHMAN, et al., "Angiotensin II and aldosterone have opposite effects on magnesium excretion in man," <i>Scot Med. J.</i> 37:157-158 (1992).	
		REMES, "Neuroendocrine activity in untreated heart failure," <i>Br Heart J</i> 65:249-255 (1991).	
		ROUX, et al., "Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm," <i>J Pharmacol Exp Ther</i> 283(3):1110-18 (1997).	
		SAKAKI, et al., "Discovery of IRL 3461: A novel and potent endothelin antagonist with balanced ET <sub>A</sub> /ET <sub>B</sub> affinity," <i>Bioorg Med Chem Lett</i> 8(16):2241-6 (1998).	
		SHEN, et al., "Defective endogenous nitric oxide-mediated modulation of cellular respiration in canine skeletal muscle after the development of heart failure," <i>J Heart Lung Transplant</i> 16(10):1026-1034 (1997).	
		SIGGERS, et al., "Serial plasma adrenaline and noradrenaline levels in myocardial infarction using a new double isotope technique," 33:878-883 (1971).	
		SIGURDSSON, et al., "Short- and long-term neurohormonal activation following acute myocardial infarction," <i>Am Heart J</i> 126:1068-1076 (1993).	

Examiner's Signature	<i>[Signature]</i>	Date Considered	4/24/04
----------------------	--------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



Approved for use through 10/31/99. PTO B 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	09/807,558
Filing Date	July 17, 2001
First Named Inventor	Stefan Dietmat Anker
Group Art Unit	1644-1647
Examiner Name	
Attorney Docket Number	ICI 102

Sheet 8 of 8

## OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
FH		SUTSCH, et al., "Short-term oral endothelial-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure," <i>Circulation</i> 98(21):2262-2268 (1998).	
		TASKER, et al., "Potent and selective non-benzodioxole-containing endothelin-A-receptor antagonists," <i>J Med Chem</i> 40:322-330 (1997).	
		The SOLVD Investigators, "Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure," <i>N Eng J Med</i> 325:293-302 (1991).	
		TOWATARI, et al., "Novel epoxysuccinyl peptides. A selective inhibitor of cathepsin B, <i>in vivo</i> ," <i>N. FEBS Lett</i> 280(2):311-5 (1991).	
		TSCHESCHE, "Bimolecular interaction of matrix metalloproteinases and their inhibitors," <i>J Protein Chem</i> 17(6):549-51 (1998).	
		TURK, et al., "Identification of bovine stefin A, a novel protein inhibitor of cysteine proteinases," <i>FEBS Lett</i> 360:101-105 (1995).	
		VETTER, et al., "Initial metabolic and hormonal response to acute myocardial infarction," <i>Lancet</i> 1:284-289 (1974).	
		WEINDEL, et al., "Inhibitory effects of the novel anti-aldosterone compound mesprenone on adrenocortical steroidogenesis <i>in vitro</i> ," <i>Arzneimittelforschung</i> 41(9):946-9 (1991).	
		ZHANG, et al., "ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption," <i>Circulation</i> 95(1):176-182 (1997).	

Examiner's Signature	<i>Ron Hand</i>	Date Considered	4/24/04
----------------------	-----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+